| REVIEW ARTICLE |
|
| Year : 2011 | Volume
: 15
| Issue : 7 | Page : 197-202 |
|
|
Adult growth hormone deficiency
Vishal Gupta
Department of Endocrinology, Jaslok Hospital and Research Centre, Mumbai, India
Correspondence Address:
Vishal Gupta
Department of Endocrinology, Jaslok Hospital and Research Centre, 15, Deshmukh Marg, Mumbai 400 026
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/2230-8210.84865
|
|
|
Adult growth hormone deficiency (AGHD) is being recognized increasingly and has been thought to be associated with premature mortality. Pituitary tumors are the commonest cause for AGHD. Growth hormone deficiency (GHD) has been associated with neuropsychiatric-cognitive, cardiovascular, neuromuscular, metabolic, and skeletal abnormalities. Most of these can be reversed with growth hormone therapy. The insulin tolerance test still remains the gold standard dynamic test to diagnose AGHD. Growth hormone is administered subcutaneously once a day, titrated to clinical symptoms, signs and IGF-1 (insulin like growth factor-1). It is generally well tolerated at the low-doses used in adults. Pegylated human growth hormone therapy is on the horizon, with a convenient once a week dosing. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
